IMUGENE LIMITED — Board/Management Information 2021

Jun 9, 2021

==> picture [116 x 42] intentionally omitted <==

ASX Announcement

Imugene Appoints Dr Monil Shah as Chief Business Officer

__________________________________________________________________________

Sydney, Australia, 10 June 2021: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Monil Shah, PharmD, MBA, as Chief Business Officer (CBO) and a member of the Company's executive management team.

Dr Shah will lead the Company’s global business development and partnering activities, and support our clinical development.

Dr Shah has over 20 years of pharmaceutical and biotechnology industry experience in oncology drug development. His most recent appointment was as Chief Development Officer at WindMIL Therapeutics, responsible for the cell therapy platform. He was the Chief Operating Officer of Brooklyn ImmunoTherapeutics leading cytokine drug development for oncology patients. Prior to that, he was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb responsible for checkpoint inhibitor development programs.

Dr Shah also was the Founder and Head of Clinical Development and Operations at Ventrus Biosciences prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr Shah led the solid tumor development programs and the Clinical Portfolio and Strategic Planning function at Celgene, as well as the Oncology Development and Operations activities at Fibrogen and Novacea. He began his career at Novartis in the Oncology Early Development Group prior to joining the Medical Sciences Group at Amgen.

Dr Shah received his Bachelor of Science in Pharmacy and Doctorate of Pharmacy degrees from Rutgers University in New Jersey.

Dr Shah stated, “With a pipeline of innovative immunotherapy vaccines and oncolytic viruses including the revolutionary CD19-CF33 onCARlytics with at potential to help solid tumor patients together with CAR T therapy, I am enthusiastic to join this wonderful team of experts at Imugene. We will continue to drive towards better and safer treatments for the benefit of patients.”

Welcoming Dr Shah, Imugene Managing Director and CEO Leslie Chong said: “We look forward to the valuable contribution Dr Shah will make to advance our important immuno-oncology programs and I’m excited by someone of his calibre and experience in cellular therapy is joining Imugene as Chief Business Officer”.

Imugene Executive Chairman Mr Paul Hopper said “Monil adds a critical business development capability to our senior management team, and we are pleased to welcome him to Imugene.”

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

For further information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

2

IMUGENE LIMITED ACN 009 179 551